PTX — Prescient Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$37.85m
- AU$29.48m
- AU$0.69m
- 64
- 14
- 78
- 54
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.42 | ||
| Price to Tang. Book | 2.7 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 74.81 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.9% | ||
| Return on Equity | -36.95% | ||
| Operating Margin | -1388.33% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.07 | 0.07 | 0.04 | 0.46 | 0.69 | n/a | n/a | 56.99% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.
Directors
- Steven Engle NEC (66)
- Steven Yatomi-Clarke CEO
- Said Sebti CSO
- Terrence Chew OTH (62)
- Melanie Leydin SEC
- James Campbell NED
- Allen Ebens NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 22nd, 1986
- Public Since
- December 19th, 1986
- No. of Shareholders
- 8,073
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 805,319,793
- Address
- L 4 100 Albert Rd, SOUTH MELBOURNE, 3205
- Web
- https://ptxtherapeutics.com/
- Phone
- +61 396927222
- Auditors
- William Buck Audit (Vic) Pty Ltd
Upcoming Events for PTX
Similar to PTX
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Prescient Therapeutics share price?
As of Today at 22:43 UTC, shares in Prescient Therapeutics are trading at AU$0.05. This share price information is delayed by 15 minutes.
How has the Prescient Therapeutics share price performed this year?
Shares in Prescient Therapeutics last closed at AU$0.05 and the price had moved by -9.62% over the past 365 days. In terms of relative price strength the Prescient Therapeutics share price has underperformed the ASX All Ordinaries Index by -12.89% over the past year.
What are the analyst and broker recommendations for Prescient Therapeutics?
The overall consensus recommendation for Prescient Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Prescient Therapeutics dividend yield?
Prescient Therapeutics does not currently pay a dividend.
Does Prescient Therapeutics pay a dividend?
Prescient Therapeutics does not currently pay a dividend.
When does Prescient Therapeutics next pay dividends?
Prescient Therapeutics does not currently pay a dividend.
How do I buy Prescient Therapeutics shares?
To buy shares in Prescient Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Prescient Therapeutics?
As of the previous close price of AU$0.05, shares in Prescient Therapeutics had a market capitalisation of AU$37.85m.
Where are Prescient Therapeutics shares listed?
Here are the trading details for Prescient Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: PTX
What kind of share is Prescient Therapeutics?
Based on an overall assessment of its quality, value and momentum Prescient Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Prescient Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Prescient Therapeutics is AU$0.20. That is 325.53% above the last closing price of AU$0.05.
Analysts covering Prescient Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Prescient Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Prescient Therapeutics. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +7.44%.
As of the last closing price of AU$0.05, shares in Prescient Therapeutics were trading +6.48% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Prescient Therapeutics PE Ratio?
The Prescient Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Prescient Therapeutics?
Prescient Therapeutics' management team is headed by:
- Steven Engle - NEC
- Steven Yatomi-Clarke - CEO
- Said Sebti - CSO
- Terrence Chew - OTH
- Melanie Leydin - SEC
- James Campbell - NED
- Allen Ebens - NED